The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy

Pharmacotherapy

Volumn 25, Issue 11 II, 2005, Pages

  Mahadevia, Parthiv J ^a,b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Amgen Inc   (United States)

Author keywords

Health care costs; Idiopathic thrombocytopenic purpura; IGIV C; IGIV S D; Immune thrombocytopenic purpura; Intravenous immunoglobulin; ITP; Primary immunodeficiency

Indexed keywords

IMMUNOGLOBULIN;

CHROMATOGRAPHY; CLINICAL TRIAL; CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PURIFICATION; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; LONG TERM CARE; PRECIPITATION; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

BLOOD PLATELETS; CAPRYLATES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY; COSTS AND COST ANALYSIS; DETERGENTS; DRUG COMPOUNDING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZED CONTROLLED TRIALS; SOLVENTS;

EID: 27644450124     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.11part2.94S     Document Type: Conference Paper

References (15)

1. Anonymous. 2003 current procedural terminology data files. Chicago, IL: American Medical Association, 2003.
2. Cohen HE, ed. Drug topics red book. Montvale, NJ: Thomson PDR, 2003.
3. Agency for Healthcare Research and Quality. Health care utilization project: nationwide inpatient sample. 9-1-200. Washington, DC: Agency for Healthcare Research and Quality, 2003.
4. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-71.
5. Knapp MJ, Colburn PA. Clinical uses of intravenous immune globulin. Clin Pharm 1990;9:509-29.
6. Stadtmauer G, Cunningham-Rundles C. Outcome analysis and cost assessment in immunologic disorders. JAMA 1997;278:2018-23.
7. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol 2003;3:1325-33.
8. Mahadevia PJ, Strell J, Kunaprayoon D, Gelfand E. Cost savings from intravenous immunoglobulin manufactured from chromatography/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder. Value Health 2005;8:488-94.
9. Simpson KN, Coughlin CM, Eron J, et al. Idiopathic thrombocytopenic purpura: treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. Semin Hematol 1998;35(suppl 1):58-64.
10. Cines D, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
11. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630-8.
12. Bussel JB, Eldor A, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004;91:771-8.
13. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344:703-7.
14. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993;123:989-95.
15. Imbach P, Wagner HP, Berchtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985;2:464-8.